ALK and non-small cell lung carcinoma: While the FDA-approved indication of lorlatinib is for advanced ALK-positive (ALK+) NSCLC, the NCCN guidelines include lorlatinib as a treatment option for patients with ROS1+ NSCLC and progression on a prior TKI based on these phase I/II trial data.17,41